A growing network of psychiatry clinics and research sites specialized in psychedelic medicine. $NM $NM.ca $NVMDF
Toronto-based psychedelic therapy research and development company.
A growing network of psychiatry clinics and research sites specialized in psychedelic medicine. $NM $NM.ca $NVMDF
March 30, 2020
Novamind Ventures closed acquisitions of Cedar Psychiatry LLC ("Cedar Psychiatry"),a specialized provider of ketamine-assisted psychotherapy and Cedar Clinical Research LLC ("Cedar Clinical Research"), a dedicated research center focused on psychedelic medicines, both based near Salt Lake City, Utah.
Total consideration paid by Novamind for the Cedar Acquisitions was CAN$3.05 million, consisting of CAN$1 million cash and CAN$2.05 million in Novamind common shares.
Toronto-based psychedelic therapy research and development company.
Novamind was founded in May 2019 in Toronto, CanadaCanada. Ongoing clinical trials approved by the U.S. Food and Drug Administration (“FDA”) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry.
Novamind was founded in May 2019 in TorontoToronto, Canada. Ongoing clinical trials approved by the U.S. Food and Drug Administration (“FDA”) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry.